Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Debu, Tripathy"'
Autor:
Hope S. Rugo, Mary Tagliaferri, Volkmar Müller, Sara M. Tolaney, Alison L. Hannah, Debu Tripathy, Nuhad K. Ibrahim, Chris Twelves, Carey K. Anders, Javier Cortes, Véronique Diéras, Andrew D. Seidman
Publikováno v:
Journal of Clinical Oncology. 36:TPS1111-TPS1111
TPS1120 Background: EP is a next generation topoisomerase I inhibitor-polymer conjugate that provides continuous exposure to SN-38, the active metabolite. A BM mouse model showed high penetration and retention of SN-38 in CNS lesions, resulting in de
Autor:
Debu Tripathy, Chen Jiang, Maura N. Dickler, Clifford A. Hudis, Alexander B. Sibley, William T. Barry, Federico Innocenti, Howard L. McLeod, Lisa A. Carey, Kouros Owzar, Flora Mulkey, Bryan P. Schneider, Eric P. Winer
Publikováno v:
Journal of Clinical Oncology. 34:538-538
538Background: CALGB 40503 testedwhether therapy with B prolongs PFS when added to first-line L as treatment of hormone receptor-positive (HR+) MBC. We aimed to identify germline variants associated with clinical outcome. Methods: Postmenopausal wome
Autor:
Caroline Bumb, Melody A. Cobleigh, Ron Bose, Rachel A. Freedman, Philippe L. Bedard, Debu Tripathy, Hussam Al-Kateb, Matthew P. Goetz, Andres Forero, Timothy J. Pluard, Polly A. Niravath, Daniel F. Hayes, Christy A. Russell, Carey K. Anders, Matthew J. Ellis, Feng Gao, Mark D. Pegram, Cynthia X. Ma, Michael Naughton, Kimberly L. Blackwell
Publikováno v:
Journal of Clinical Oncology. 34:516-516
516Background: HER2 mutation occurs in ~2% of breast cancer (BC). Preclinical models suggested neratinib, an irreversible HER2/EGFR tyrosine kinase inhibitor, could be an effective treatment. This trial was conducted to assess the clinical benefit ra
Autor:
Limin Hsu, Debu Tripathy, Isabelle Bedrosian, Carlos H. Barcenas, Modesto Patangan, Therese B. Bevers, Huong T. Le-Petross, Arup Kumar Sinha, Akshara Singareeka Raghavendra
Publikováno v:
Journal of Clinical Oncology. 34:260-260
260 Background: Female breast cancer survivors have an average lifetime risk of 4-8% to develop a contralateral breast cancer (CBC).It is unclear if the tumor stage of the first breast cancer is associated with the development of a second CBC. Method
Autor:
Debu Tripathy, Richard Sposto, Agustin A. Garcia, Darcy V. Spicer, Caitlin Bertelsen, Lingyun Ji, Christy A. Russell
Publikováno v:
Journal of Clinical Oncology. 30:1065-1065
1065 Background: The FDA-approved dose of capecitabine (cape) of 1250mg/m2 twice daily (BID) is associated with treatment-limiting toxicities. Published reports suggest that lower starting doses of cape can be as effective as the approved dose in tre